Ulmer J B, Sadoff J C, Liu M A
Department of Virus & Cell Biology, Merck Research Laboratories, WP 16-101, West Point, PA 19486, USA.
Curr Opin Immunol. 1996 Aug;8(4):531-6. doi: 10.1016/s0952-7915(96)80042-2.
Preclinical DNA vaccine development has continued apace during the past year, with the investigation of several new infectious and non-infectious disease targets as well as advances in our understanding of some of the basic immunologic mechanisms, such as effector cells, responsible for conferring protection. The coming year promises to be at least as exciting, as initial human clinical studies have begun.
在过去一年中,临床前DNA疫苗的研发进展迅速,对多种新的感染性和非感染性疾病靶点进行了研究,并且我们对一些基本免疫机制(如负责提供保护的效应细胞)的理解也取得了进展。随着首批人体临床研究的启动,来年有望同样令人振奋。